hERG Inhibitors
1 drugsAbout hERG
The human Ether-à-go-go-Related Gene (hERG), also known as KCNH2, encodes a potassium ion channel crucial for cardiac repolarization. This channel regulates the heart's electrical activity, allowing the heart muscle to reset between beats.
hERG is a critical target in drug development for assessing cardiotoxicity. Blocking the hERG channel can prolong the QT interval, potentially leading to Torsades de Pointes. There is no genetic evidence data available for this target.
hERG is targeted by one FDA-approved drug, RANOLAZINE, a small molecule. I3 PHARMS is the only company with an approved drug targeting hERG.
Top hERG Drugs
I3 PHARMS is the only company with an approved drug targeting hERG.
Low market concentration indicates a potential opportunity for new entrants, but also high barriers to entry.
hERG Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets hERG, using small molecule modality.
The limited modality diversity suggests an opportunity to explore alternative modalities like antibodies or peptides.
hERG Clinical Trials 56 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on hERG. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 8 | 8 | 0 | 0 | 100% |
| Phase 2 | 22 | 12 | 7 | 3 | 63% |
| Phase 3 | 10 | 8 | 2 | 0 | 80% |
| Phase 4 | 16 | 10 | 6 | 0 | 63% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
hERG Drug Approval Timeline (2013 - 2013)
The first and only drug targeting hERG, RANOLAZINE, was approved in 2013.
The single approval in 2013 suggests a saturated market or challenges in developing hERG-modulating drugs.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 38 (5 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on hERG. A trial counts if an approved drug acting on hERG is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.